Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2477-2488

  Murphy, Diarmaid J ^a   Desjardins, Delphine ^b,c   Dereuddre Bosquet, Nathalie ^b,c   Brochard, Patricia ^b,c   Perrot, Ludivine ^b,c   Pruvost, Alain ^d   Grand, Roger Le ^b,c   Lagatie, Ole ^e   Vanhooren, Leen ^e   Feyaerts, Maxim ^e   van Roey, Jens ^e   Malcolm, R Karl ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Institut National de la Recherche Agronomique   (France)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Cynomolgus macaques; HIV microbicides; Pharmacokinetics; Silicone elastomer vaginal rings

Indexed keywords

2 PROPANOL; DAPIVIRINE; DARUNAVIR; EMLA; ETHINYLESTRADIOL PLUS ETONOGESTREL; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; PROGESTERONE; SILASTIC; WATER; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TMC120-R147681;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG RECTUM LEVEL; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG UTERINE CERVIX LEVEL; DRUG UTERUS LEVEL; DRUG VAGINA LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROGEN BOND; IC 50; LUTEAL PHASE; MACACA; MACACA FASCICULARIS; MELTING POINT; NONHUMAN; PROGESTERONE BLOOD LEVEL; RECTUM; SEXUAL TRANSMISSION; SILICONE ELASTOMER VAGINAL RING; THERMOGRAPHY; UTERINE CERVIX; UTERUS; VAGINA; VAGINA DISCHARGE; VAGINA RING; ANIMAL; BODY FLUID; CHEMISTRY; DISEASE MODEL; DISEASE TRANSMISSION; DRUG COMBINATION; FEMALE CONTRACEPTIVE DEVICE; HIV INFECTIONS; HUMAN; IC50; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES;

ANIMALS; ANTI-HIV AGENTS; BODY FLUIDS; CERVIX UTERI; CONTRACEPTIVE DEVICES, FEMALE; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MACACA; PRE-EXPOSURE PROPHYLAXIS; PYRIMIDINES; RECTUM; SULFONAMIDES; UTERUS; VAGINA;

EID: 84905976929     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku160     Document Type: Article

References (37)

1. Malcolm RK, Woolfson AD, Toner CF et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 954-6.
2. Nel A, Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-23.
3. Romano J, Variano B, Coplan P et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 483-8.
4. Clark JT, Johnson TJ, Clark MR et al. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release 2012; 163: 240-8.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
6. Pirrone V, Thakkar N, Jacobson JM et al. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011; 55: 1831-42.
7. Malcolm RK, Fetherston SM. Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. Contraception 2013; 88: 321-5.
8. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2: a007385.
9. Malcolm RK, Veazey RS, Geer L et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56: 2251-8.
10. Saxena BB, Han YA, Fu D et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 2009; 23: 917-22.
11. Fetherston SM, Boyd P, Mccoy CF et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur J Pharm Sci 2013; 48: 406-15.
12. Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011; 6: e15835.
13. Kenney J, Singer R, Derby N et al. A single dose of a MIV-150/zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses 2012; 28: 1476-84.
14. Wensing AMJ, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 2010; 85: 59-74.
15. Herrera C, Shattock RJ. Potential use of protease inhibitors as vaginal and colorectal microbicides. Curr HIV Res 2012; 10: 42-52.
16. Owen DH, Katz DF. Avaginal fluid simulant. Contraception 1999; 59: 91-5.
17. Promadej-Lanier N, Smith JM, Srinivasan P et al. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J Med Primatol 2009; 38: 263-71.
18. Woolfson AD, Malcolm RK, Morrow RJ et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325: 82-9.
19. Gupta KM, Pearce SM, Poursaid AE et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 2008; 97: 4228-39.
20. Van Gyseghem E, Stokbroekx S, de Armas HN et al. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009; 38: 489-97.
21. Liu J, Hameed N, Guo Q. Eutectic crystallization and hydrogen bonding interactions in polymer/surfactant blends. J Polym Sci Part B Polym Phys 2009; 47: 1015-23.
22. Liang YH, Chen FE. ONIOM DFT/PM3 calculations on the interaction between dapivirine and HIV-1 reverse transcriptase, a theoretical study. Drug Discov Ther 2007; 1: 57-60.
23. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961; 50: 874-5.
24. Malcolm K, Woolfson D, Russell J et al. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release 2003; 90: 217-25.
25. Di Colo G, Carelli V, Nannipieri E et al. Effect of different water-soluble additives on the sustained release of sulfanilamide from silicone rubber matrices. Farmaco Prat 1983; 37: 377-89.
26. Fetherston SM, Geer L, Veazey RS et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 2013; 68: 394-403.
27. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73: 1253-63.
28. De Ziegler D, Bulletti C, De Monstier B et al. The first uterine pass effect. Ann N Y Acad Sci 1997; 828: 291-9.
29. Bulletti C, de Ziegler D, Flamigni C et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997; 12: 1073-9.
30. Malcolm RK, Lowry D, Boyd P et al. Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. J Antimicrob Chemother 2014; 69: 1325-9.
31. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52: 1145-9.
32. Fernández-Romero JA, Thorn M, Turville SG et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34: 9-14.
33. Johnson TJ, Gupta KM, Fabian J et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010; 39: 203-12.
34. Ham AS, Ugaonkar SR, Shi L et al. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci 2012; 101: 1423-35.
35. Dezzutti CS, Shetler C, Mahalingam A et al. Safety and efficacy of tenofovir/IQP-0528 combination gels-a dual compartment microbicide for HIV-1 prevention. Antiviral Res 2012; 96: 221-5.
36. Kiser PF, Mahalingam A, Fabian J et al. Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci 2012; 101: 1852-64.
37. D'Cruz OJ, Uckun FM. Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. Fertil Steril 2007; 88: 1197-206.